Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases;Leitlinie zur (allergen-) spezifischen Immuntherapie bei IgE-vermittelten allergischen Erkrankungen

Allergo Journal

Volumn 23, Issue 8, 2014, Pages 28-67

  Pfaar, Oliver ^a   Bachert, Claus ^b   Bufe, Albrecht ^c   Buhl, Roland ^d   Ebner, Christof ^e   Eng, Peter ^f   Friedrichs, Frank ^g   Fuchs, Thomas ^h   Hamelmann, Eckard ⁱ   Hartwig Bade, Doris ^j   Hering, Thomas ^k   Huttegger, Isidor ^l   Jung, Kirsten ^m   Klimek, Ludger ^a   Kopp, Matthias Volkmar ⁿ   Merk, Hans ^o   Rabe, Uta ^p   Saloga, Joachim ^d   Schmid Grendelmeier, Peter ^q   Schuster, Antje ^r   Schwerk, Nicolaus ^s   Sitter, Helmut ^t   Umpfenbach, Ulrich ^u   Wedi, Bettina ^s   Wöhrl, Stefan ^v   Worm, Margitta ^w   Kleine Tebbe, Jörg ^x   Kaul, Susanne ^y   Schwalfenberg, Anja ^z   more..

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c RUHR UNIVERSITY BOCHUM   (Germany)

^d UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^e Ambu latorium für Allergie und Klinische Immunologie   (Austria)

^f Klinik für Kinder und Jugendliche   (Switzerland)

^g Praxis für Kinder und Jugendmedizin   (Germany)

^h UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

ⁱ EVANGELISCHES KRANKENHAUS   (Germany)

^j Hals Nasen Ohrenarzt Praxis   (Germany)

^k Lungenarztpraxis Tegel   (Germany)

^l Salzburger Landeskliniken   (Austria)

^m Praxis fur Dermatologie und Immunologie   (Germany)

ⁿ UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^o RWTH AACHEN UNIVERSITY   (Germany)

^p Klinik III   (Germany)

^q UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^r UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^s HANNOVER MEDICAL SCHOOL   (Germany)

^t PHILIPPS UNIVERSITY MARBURG   (Germany)

^u Praxis für Kinder und Jugendmedizin   (Germany)

^v FAZ Floridsdorfer Allergiezentrum   (Austria)

^w CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^x Allergie und Asthma Zentrum Westend   (Germany)

^y PAUL EHRLICH INSTITUT   (Germany)

^z Deutscher Allergie und Asthmabund   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; IMMUNOGLOBULIN E;

ALLERGIC DISEASE; IMMUNOTHERAPY; PRACTICE GUIDELINE; REVIEW;

EID: 84937143245     PISSN: 09418849     EISSN: 21956405     Source Type: Journal    
DOI: 10.1007/s40629-014-0032-2     Document Type: Review

References (221)

1. Kleine-Tebbe J, Bufe A, Ebner C et al. Die spezifische Immuntherapie (Hyposensibilisierung) bei IgE-vermittelten allergischen Erkrankungen. Leitlinie der Deutschen Gesellschaft fü r Allergologie und klinische Immunologie (DGAKI), des Ä rzteverbandes Deutscher Allergologen (Ä DA), der Gesellschaft fü r Pä diatrische Allergologie und Umweltmedizin (GPA), der Ö sterreichischen Gesellschaft fü r Allergologie und Immunologie (Ö GAI) und der Schweizerischen Gesellschaft fü r Allergologie und Immunologie (SGAi). Allergo J 2009;18:509-37
2. Bagnasco M, Altrinetti V, Pesce G et al. Pharmacokinetics of der p 2 allergen and derived monomeric allergoid in allergic volunteers. Int Arch Allergy Immunol 2005;138:197-202
3. Martinez-Gómez JM, Johansen P, Erdmann I, Senti G, Crameri R, Kündig TM. Intralymphatic injections as a new administration route for allergen-specific immunotherapy. Int Arch Allergy Immunol 2009;150:59-65
4. Allam JP, Würtzen PA, Reinartz M et al. Phl p 5 resorption in human oral mucosa leads to dose-dependent and time-dependent allergen binding by oral mucosal Langerhans cells, attenuates their maturation, and enhances their migratory and TGF-beta1 and IL-10-producing properties. J Allergy Clin Immunol 2010;126:638-45.e1
5. Akdis M, Akdis CA. Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol 2007;119:780-91
6. Nouri-Aria KT, Wachholz PA, Francis JN et al. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol 2004;172:3252-9
7. Takhar P, Smurthwaite L, Coker HA et al. Allergen drives class switching to IgE in the nasal mucosa in allergic rhinitis. J Immunol 2005;174:5024-32
8. Reisinger J, Horak F, Pauli G et al. Allergen-specific nasal IgG antibodies induced by vaccination with genetically modified allergens are associated with reduced nasal allergen sensitivity. J Allergy Clin Immunol 2005;116:347-54
9. Akdis M, Verhagen J, Taylor A et al. Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J Exp Med 2004;199:1567-75
10. Li JT, Lockey RF, Bernstein I, Portnoy JM, Nicklas RA. Allergen immunotherapy: a practice parameter. American Academy of Allergy, Asthma and Immunology. American College of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 2003;90(1 Suppl 1):1-40
11. European Medicines Agency; Committee for medicinal products for human use (CHMP). Guideline on allergen products: production and quality issues. EMEA/CHMP/BWP/304831/2007. London, 20 November, 2008
12. Van Ree R, Chapman MD, Ferreira F et al. The CREATE project: development of certified reference materials for allergenic products and validation of methods for their quantification. Allergy 2008;63:310-26
13. European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, eds. Monograph: Allergen Products - Producta Allergenica 07/2014:1063. as implemented of 01.07.2014. Strasbourg: Council of Europe; 2014:p. 3945-47
14. Grammer LC, Shaughnessy MA, Patterson R. Modified forms of allergen immunotherapy. J Allergy Clin Immunol 1985;76:397-401
15. Pfaar O, Kleine-Tebbe J, Hörmann K, Klimek L. Allergenspecific immunotherapy: which outcome measures are useful in monitoring clinical trials? Immunol Allergy Clin North Am 2011;31:289-309
16. Calderon MA, Eichel A, Makatsori M, Pfaar O. Comparability of subcutaneous and sublingual immunotherapy outcomes in allergic rhinitis clinical trials. Curr Opin Allergy Clin Immunol 2012;12:249-56
17. Pfaar O, Demoly P, Gerth Van Wijk R et al. Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper. Allergy 2014;69:854-67
18. Grouin JM, Vicaut E, Jean-Alphonse S et al. The average adjusted symptom score, a new primary efficacy endpoint for specific allergen immunotherapy trials. Clin Exp Allergy 2011;41:1282-8
19. Didier A, Melac M, Montagut A, Lheritier-Barrand M, Tabar A, Worm M. Agreement of efficacy assessments for five-grass pollen sublingual tablet immunotherapy. Allergy 2009;64:166-71
20. Clark J, Schall R. Assessment of combined symptom and medication scores for rhinoconjunctivitis immunotherapy clinical trials. Allergy 2007;62:1023-8
21. European Medicines Agency; Commitee for medicinal products for human use (CHMP), eds. Guideline on the clinical development of products for specific immunotherapy for the treatment of allergic diseases. CHMP/EWP/18504/2006. London, 20. November 2008
22. Bousquet J, Schünemann HJ, Bousquet PJ et al. How to design and evaluate randomized controlled trials in immunotherapy for allergic rhinitis: an ARIA-GA (2) LEN statement. Allergy 2011;66:765-74
23. Bousquet PJ, Brozek J, Bachert C et al. The CONSORT statement checklist in allergen-specific immunotherapy: a GA2LEN paper. Allergy 2009;64:1737-45
24. Brehler R, Klimek L, Kopp MV, Christian Virchow J. Specific immunotherapy-indications and mode of action. Dtsch Arztebl Int 2013;110:148-58
25. Verordnung ü ber die Ausdehnung der Vorschriften ü ber die Zulassung der Arzneimittel auf Therapieallergene, die fü r einzelne Personen auf Grund einer Rezeptur hergestellt werden, sowie ü ber Verfahrensregelungen der staatlichen Chargenprü fung (Therapieallergene-Verordnung). Bundesgesetzbl 2008;51:2177-8
26. Englert S, May S, Kaul S, Vieths S. Die Therapieallergene-Verordnung. Hintergrund und Auswirkungen. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz 2012;55:351-57
27. Kaul S, Jappe U, Vieths S, May S. Überwachung von Allergenextrakten zur spezifischen Immuntherapie: rechtliche Grundlagen und Verfahren. Allergo J 2008;17:385-93
28. May S, Haustein D. Die individuelle Rezeptur in der spezifischen Immuntherapie. Notwendigkeit und Fehlerquellen. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz 2001;44:719-23
29. Incorvaia C, Agostinis F, Amoroso S et al. Pharmacoeconomics of subcutaneous allergen immunotherapy. Eur Ann Allergy Clin Immunol 2007;39 Spec No: 17-20
30. Incorvaia C, Mauro M, Ridolo E et al. Patient's compliance with allergen immunotherapy. Patient Prefer Adherence 2008;2:247-51
31. Bocking C, Renz H, Pfefferle PI. Prävalenz und sozioökonomische Bedeutung von Allergien in Deutschland. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz 2012;55:303-7
32. Lamb CE, Ratner PH, Johnson CE et al. Economic impact of workplace productivity losses due to allergic rhinitis compared with select medical conditions in the United States from an employer perspective. Curr Med Res Opin 2006;22:1203-10
33. Shaaban R, Zureik M, Soussan D et al. Rhinitis and onset of asthma: a longitudinal population-based study. Lancet 2008;372:1049-57
34. Jacobsen L, Niggemann B, Dreborg S et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy 2007;62:943-8
35. Hagen A, Gorenoi V, Schonermark MP. Specific immunotherapy (SIT) in the treatment of allergic rhinitis. GMS Health Technol Assess 2010;6:Doc01 doi: 10.3205/hta000079
36. ®)) in children. Clinicoecon Outcomes Res 2014;6:187-96
37. Brüggenjürgen B, Reinhold T, Brehler R et al. Cost-effectiveness of specific subcutaneous immunotherapy in patients with allergic rhinitis and allergic asthma. Ann Allergy Asthma Immunol 2008;101:316-24
38. Westerhout KY, Verheggen BG, Schreder CH, Augustin M. Cost effectiveness analysis of immunotherapy in patients with grass pollen allergic rhinoconjunctivitis in Germany. J Med Econ 2012;15:906-17
39. Schädlich PK and Brecht JG. Economic evaluation of specific immunotherapy versus symptomatic treatment of allergic rhinitis in Germany. Pharmacoeconomics 2000;17:37-52
40. Bachert C. Comparison of solutions for sublingual immunotherapy. Int Arch Allergy Immunol 2007;142:89-90
41. Calderon MA, Casale TB, Togias A, Bousquet J, Durham SR, Demoly P. Allergen-specific immunotherapy for respiratory allergies: from meta-analysis to registration and beyond. J Allergy Clin Immunol 2011;127:30-8
42. Compalati E, Penagos M, Tarantini F, Passalacqua G, Canonica GW. Specific immunotherapy for respiratory allergy: state of the art according to current meta-analyses. Ann Allergy Asthma Immunol 2009;102:22-8
43. Calderon M, Mösges R, Hellmich M, Demoly P. Towards evidence-based medicine in specific grass pollen immunotherapy. Allergy 2010;65:420-34
44. Dretzke J, Meadows A, Novielli N, Huissoon A, Fry-Smith A, Meads C. Subcutaneous and sublingual immunotherapy for seasonal allergic rhinitis: a systematic review and indirect comparison. J Allergy Clin Immunol 2013;131:1361-6
45. Calderon MA, Casale TB, Nelson HS, Demoly P. An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies. J Allergy Clin Immunol 2013;132:1322-36
46. Canonica GW, Baena-Cagnani CE, Bousquet J et al. Recommendations for standardization of clinical trials with allergen specific immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce. Allergy 2007;62:317-24
47. Carr W, Bernstein J, Lieberman P et al. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. J Allergy Clin Immunol 2012;129:1282-9.e10
48. Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev 2007;1:CD001936
49. Matricardi PM, Kuna P, Panetta V, Wahn U, Narkus A. Subcutaneous immunotherapy and pharmacotherapy in seasonal allergic rhinitis: a comparison based on metaanalyses. J Allergy Clin Immunol 2011;128:791-9.e6
50. Kuna P, Kaczmarek J, Kupczyk M. Efficacy and safety of immunotherapy for allergies to Alternaria alternata in children. J Allergy Clin Immunol 2011;127:502-8.e1-6
51. Bergmann KC. Spezifische Immuntherapie bei allergischem Asthma bronchiale. Pneumologie 2003;57:84-90
52. Bousquet J, Lockey RF, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. WHO Position paper. Allergy 1998;53(44 Suppl):1-42
53. Buhl R, Berdel D, Criée CP et al. Leitlinie zur Diagnostik und Therapie von Patienten mit Asthma. Pneumologie 2006;60:139-83
54. Gillissen A, Bergmann KC, Kleine-Tebbe J et al. Die spezifische Immuntherapie bei allergischem Asthma. Dtsch Med Wochenschr 2003;128:204-9
55. Global Initiative for Asthma (GINA), ed. Global strategy for asthma management and prevention (updated 2005). www.ginasthma.org
56. Global Initiative for Asthma (GINA), ed. Global strategy for asthma management and prevention (updated 2007). www.ginasthma.org
57. Walker SM, Durham SR, Till SJ et al. Immunotherapy for allergic rhinitis. Clin Exp Allergy 2011;41:1177-200
58. Bousquet J. Specific immunotherapy in asthma. Allergy 1999;54 Suppl 56:37-8
59. Abramson MJ, Puy RM, Weiner JM. Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev 2010;8:CD001186
60. Amin HS, Liss GM, Bernstein DI. Evaluation of near-fatal reactions to allergen immunotherapy injections. J Allergy Clin Immunol 2006;117:169-75
61. Zielen S, Kardos P, Madonini E. Steroid-sparing effects with allergen-specific immunotherapy in children with asthma: a randomized controlled trial. J Allergy Clin Immunol 2010;126:942-9
62. Frew AJ, Powell RJ, Corrigan CJ, Durham SR. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006;117:319-25
63. Corrigan CJ, Kettner J, Doemer C, Cromwell O, Narkus A. Efficacy and safety of preseasonal-specific immunotherapy with an aluminium-adsorbed six-grass pollen allergoid. Allergy 2005;60:801-7
64. Pfaar O, Urry Z, Robinson DS et al. A randomized placebocontrolled trial of rush preseasonal depigmented polymerized grass pollen immunotherapy. Allergy 2012;67:272-9
65. Dubuske L, Frew A, Horak F et al. Ultrashort-specific immunotherapy successfully treats seasonal allergic rhinoconjunctivitis to grass pollen. Allergy Asthma Proc 2011;32:239-47
66. Brewczynski P, Kroon A. Wirksamkeit und Verträglichkeit einer Immuntherapie mit modifizierten Gräserpollenallergenen. Allergologie 1999;22:411-20
67. Roberts G, Hurley C, Turcanu V, Lack G. Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthma. J Allergy Clin Immunol 2006;117:263-8
68. Arvidsson MB, Löwhagen O, Rak S. Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy. J Allergy Clin Immunol 2002;109:777-83
69. Balda BR, Wolf H, Baumgarten C et al. Tree-pollen allergy is efficiently treated by short-term immunotherapy (STI) with seven preseasonal injections of molecular standardized allergens. Allergy 1998;53:740-8
70. Bødtger U, Poulsen LK, Jacobi HH, Malling HJ. The safety and efficacy of subcutaneous birch pollen immunotherapy - a one-year, randomised, double-blind, placebo-controlled study. Allergy 2002;57:297-305
71. Van Neerven RJ, Arvidsson M, Ipsen H, Sparholt SH, Rak S, Würtzen PA. A double-blind, placebo-controlled birch allergy vaccination study: inhibition of CD23-mediated serum-immunoglobulin E-facilitated allergen presentation. Clin Exp Allergy 2004;34:420-8
72. Hoiby AS, Strand V, Robinson DS, Sager A, Rak S. Efficacy, safety, and immunological effects of a 2-year immunotherapy with Depigoid birch pollen extract: a randomized, double-blind, placebo-controlled study. Clin Exp Allergy 2010;40:1062-70
73. Pfaar O, Robinson DS, Sager A, Emuzyte R. Immunotherapy with depigmented-polymerized mixed tree pollen extract: a clinical trial and responder analysis. Allergy 2010;65:1614-21
74. Drachenberg KJ, Heinzkill M, Urban E. Kurzzeit-Immuntherapie mit Baumpollen-Allergoiden und dem Adjuvanz Monophosphoryl Lipid A. Ergebnisse einer randomisierten, doppelblinden, plazebokontrollierten Multicenterstudie. Allergologie 2002;25:466-74
75. Ameal A, Vega-Chicote JM, Fernández S et al. Doubleblind and placebo-controlled study to assess efficacy and safety of a modified allergen extract of Dermatophagoides pteronyssinus in allergic asthma. Allergy 2005;60:1178-83
76. Pichler CE, Marquardsen A, Sparholt S et al. Specific immunotherapy with Dermatophagoides pteronyssinus and D.farinae results in decreased bronchial hyperreactivity. Allergy 1997;52:274-83
77. Riechelmann H, Schmutzhard J, Van Der Werf JF, Distler A, Kleinjans HA. Efficacy and safety of a glutaraldehydemodified house dust mite extract in allergic rhinitis. Am J Rhinol Allergy 2010;24:e104-9
78. Varney VA, Tabbah K, Mavroleon G, Frew AJ. Usefulness of specific immunotherapy in patients with severe perennial allergic rhinitis induced by house dust mite: a double-blind, randomized, placebo-controlled trial. Clin Exp Allergy 2003;33:1076-82
79. Blainey AD, Phillips MJ, Ollier S, Davies RJ. Hyposensitization with a tyrosine adsorbed extract of Dermatophagoides pteronyssinus in adults with perennial rhinitis. A controlled clinical trial. Allergy 1984;39:521-8
80. Yukselen A, Kendirli SG, Yilmaz M, Altintas DU, Karakoc GB. Effect of one-year subcutaneous and sublingual immunotherapy on clinical and laboratory parameters in children with rhinitis and asthma: a randomized, placebo-controlled, double-blind, double-dummy study. Int Arch Allergy Immunol 2012;157:288-98
81. Olsen OT, Larsen KR, Jacobsan L, Svendsen UG. A 1-year, placebo-controlled, double-blind house-dust-mite immunotherapy study in asthmatic adults. Allergy 1997;52:853-9
82. Wang H, Lin X, Hao C et al. A double-blind, placebo-controlled study of house dust mite immunotherapy in Chinese asthmatic patients. Allergy 2006;61:191-7
83. Garcia-Robaina JC, Sanchez I, De La Torre F, Fernandez-Caldas E, Casanovas M. Successful management of miteallergic asthma with modified extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae in a double-blind, placebo-controlled study. J Allergy Clin Immunol 2006;118:1026-32
84. Blumberga G, Groes L, Haugaard L, Dahl R. Steroid-sparing effect of subcutaneous SQ-standardised specific immunotherapy in moderate and severe house dust mite allergic asthmatics. Allergy 2006;61:843-8
85. Bucur J, Dreborg S, Einarsson R. Immunotherapy with dog and cat allergen preparations in dog-sensitive and cat-sensitive asthmatics. Ann Allergy 1989;62:355-61
86. Hedlin G, Graff-Lonnevig V, Heilborn H et al. Immunotherapy with cat- and dog-dander extracts. V. Effects of 3 years of treatment. J Allergy Clin Immunol 1991;87:955-64
87. Hedlin G, Heilborn H, Lilja G et al. Long-term follow-up of patients treated with a three-year course of cat or dog immunotherapy. J Allergy Clin Immunol 1995;96:879-85
88. Nanda A, O'Connor M, Anand M et al. Dose dependence and time course of the immunologic response to administration of standardized cat allergen extract. J Allergy Clin Immunol 2004;114:1339-44
89. Sundin B, Lilja G, Graff-Lonnevig V et al. Immunotherapy with partially purified and standardized animal dander extracts. I. Clinical results from a double-blind study on patients with animal dander asthma. J Allergy Clin Immunol 1986;77:478-87
90. Dreborg S, Agrell B, Foucard T, Kjellman NI, Koivikko A, Nilsson S. A double-blind, multicenter immunotherapy trial in children, using a purified and standardized Cladosporium herbarum preparation. I. Clinical results. Allergy 1986;41:131-40
91. Horst M, Hejjaoui A, Horst V, Michel FB, Bousquet J. Double-blind, placebo-controlled rush immunotherapy with a standardized Alternaria extract. J Allergy Clin Immunol 1990;85:460-72
92. Malling HJ, Dreborg S, Weeke B. Diagnosis and immunotherapy of mould allergy. V. Clinical efficacy and side effects of immunotherapy with Cladosporium herbarum. Allergy 1986;41507-19
93. Mari A, Ballmer-Weber BK, Vieths S. The oral allergy syndrome: improved diagnostic and treatment methods. Curr Opin Allergy Clin Immunol 2005;5:267-73
94. Mauro M, Russello M, Incorvaia C et al. Birch-apple syndrome treated with birch pollen immunotherapy. Int Arch Allergy Immunol 2011;156:416-22
95. Bussmann C, Böckenhoff A, Henke H, Werfel T, Novak N. Does allergen-specific immunotherapy represent a therapeutic option for patients with atopic dermatitis? J Allergy Clin Immunol 2006;118:1292-8
96. Novak N. Allergen specific immunotherapy for atopic dermatitis. Curr Opin Allergy Clin Immunol 2007;7:542-46
97. Werfel T, Breuer K, Rueff F et al. Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi-centre, randomized, dose-response study. Allergy 2006;61:202-5
98. Novak N, Bieber T, Hoffmann M et al. Efficacy and safety of subcutaneous allergen-specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. J Allergy Clin Immunol 2012;130:925-31.e4
99. Bae JM, Choi YY, Park CO, Chung KY, Lee KH. Efficacy of allergen-specific immunotherapy for atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials. J Allergy Clin Immunol 2013;132:110-7
100. Dahl R, Stender A, Rak S. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis. Allergy 2006;61:185-90
101. Dahl R, Kapp A, Colombo G et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006;118:434-40
102. Didier A, Malling HJ, Worm M et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 2007;120:1338-45
103. Worm M. Efficacy and tolerability of high dose sublingual immunotherapy in patients with rhinoconjunctivitis. Allerg Immunol (Paris) 2006;38:355-60
104. Durham SR, Yang WH, Pedersen MR, Johansen N, Rak S. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006;117:802-9
105. Worm M, Rak S, De Blay F et al. Sustained efficacy and safety of a 300IR daily dose of a sublingual solution of birch pollen allergen extract in adults with allergic rhinoconjunctivitis: results of a double-blind, placebo-controlled study. Clin Transl Allergy 2014;4:7
106. Bergmann KC, Demoly P, Worm M et al. Efficacy and safety of sublingual tablets of house dust mite allergen extracts in adults with allergic rhinitis. J Allergy Clin Immunol 2014;133:1608-14.e6
107. Bufe A, Eberle P, Franke-Beckmann E et al. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. J Allergy Clin Immunol 2009;123:167-73.e7
108. Wahn U, Tabar A, Kuna P et al. Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J Allergy Clin Immunol 2009;123:160-6.e3
109. Wahn U, Klimek L, Ploszczuk A et al. High-dose sublingual immunotherapy with single-dose aqueous grass pollen extract in children is effective and safe: a doubleblind, placebo-controlled study. J Allergy Clin Immunol 2012;130:886-93.e5
110. Radulovic S, Calderon MA, Wilson D, Durham S. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev 2010;(12): CD002893
111. Wilson DR, Torres LI, Durham SR. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev 2003;(2): CD002893
112. Khinchi MS, Poulsen LK, Carat F, Andre C, Hansen AB, Malling HJ. Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, doubledummy study. Allergy 2004;59:45-53
113. Devillier P, Dreyfus JF, Demoly P, Calderon MA. A metaanalysis of sublingual allergen immunotherapy and pharmacotherapy in pollen-induced seasonal allergic rhinoconjunctivitis. BMC medicine 2014;12:71
114. Bousquet J, Scheinmann P, Guinnepain MT et al. Sublingual-swallow immunotherapy (SLIT) in patients with asthma due to house-dust mites: a double-blind, placebo-controlled study. Allergy 1999;54:249-60
115. Pajno GB, Morabito L, Barberio G, and Parmiani S. Clinical and immunologic effects of long-term sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, placebo-controlled study. Allergy 2000;55:842-9
116. Hirsch T, Sahn M, Leupold W. Double-blind placebo-controlled study of sublingual immunotherapy with house dust mite extract (D.pt.) in children. Pediatr Allergy Immunol 1997;8:21-7
117. Bahceciler NN, Isik U, Barlan IB, Basaran MM. Efficacy of sublingual immunotherapy in children with asthma and rhinitis: a double-blind, placebo-controlled study. Pediatr Pulmonol 2001;32:49-55
118. Mosbech H, Deckelmann R, De Blay F et al. Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 2014;134:568-75.e7
119. Nelson HS, Nolte H, Creticos P, Maloney J, Wu J, Bernstein DI. Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults. J Allergy Clin Immunol 2011;127:72-80.e1-2
120. Canonica GW, Cox L, Pawankar R et al. Sublingual immunotherapy: World Allergy Organization position paper 2013 update. The World Allergy Organization journal 2014;7:6
121. Pajno GB, Caminiti L, Crisafulli G et al. Direct comparison between continuous and coseasonal regimen for sublingual immunotherapy in children with grass allergy: a randomized controlled study. Pediatr Allergy Immunol 2011;22:803-7
122. Blaiss M, Maloney J, Nolte H, Gawchik S, Yao R, Skoner DP. Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents. J Allergy Clin Immunol 2011;127:64-71.e1-4
123. Didier A, Malling HJ, Worm M et al. Post-treatment efficacy of discontinuous treatment with 300IR 5-grass pollen sublingual tablet in adults with grass pollen-induced allergic rhinoconjunctivitis. Clin Exp Allergy 2013;43:568-77
124. Durham SR, Emminger W, Kapp A et al. Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. J Allergy Clin Immunol 2010;125:131-8.e1-7
125. Durham SR, Emminger W, Kapp A et al. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol 2012;129:717-25. e5
126. Ott H, Sieber J, Brehler R et al. Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT study. Allergy 2009;64:179-86
127. Pfaar O, Klimek L. Efficacy and safety of specific immunotherapy with a high-dose sublingual grass pollen preparation: a double-blind, placebo-controlled trial. Ann Allergy Asthma Immunol 2008;100:256-63
128. Drachenberg K, Pfeiffer P, Urban E. Sublingual Immuntherapie. Ergebnisse einer randomisierten, doppelblinden, plazebokontrollierten Multicenterstudie mit einem standardisierten Birken- und Gräser-/Roggenpollenextrakt. Allergologie 2001;24:525-34
129. Horak F, Stübner P, Berger UE, Marks B, Toth J, Jäger S. Immunotherapy with sublingual birch pollen extract. A short-term double-blind placebo study. J Investig Allergol Clin Immunol 1998;8:165-71
130. Tonnel AB, Scherpereel A, Douay B et al. Allergic rhinitis due to house dust m ites: evaluation of the efficacy of specific sublingual immunotherapy. Allergy 2004;59:491-7
131. Passalacqua G, Albano M, Fregonese L et al. Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis. Lancet 1998;351:629-32
132. Lue KH, Lin YH, Sun HL, Lu KH, Hsieh JC, Chou MC. Clinical and immunologic effects of sublingual immunotherapy in asthmatic children sensitized to mites: a doubleblind, randomized, placebo-controlled study. Pediatr Allergy Immunol 2006;17:408-15
133. Niu CK, Chen WY, Huang JL, Lue KH, Wang JY. Efficacy of sublingual immunotherapy with high-dose mite extracts in asthma: a multi-center, double-blind, randomized, and placebo-controlled study in Taiwan. Respir Med 2006;100:1374-83
134. Passalacqua G, Pasquali M, Ariano R et al. Randomized double-blind controlled study with sublingual carbamylated allergoid immunotherapy in mild rhinitis due to mites. Allergy 2006;61:849-54
135. Guez S, Vatrinet C, Fadel R, Andre C. House-dust-mite sublingual-swallow immunotherapy (SLIT) in perennial rhinitis: a double-blind, placebo-controlled study. Allergy 2000;55:369-75
136. Möller C, Dreborg S, Ferdousi HA et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002;109:251-6
137. Niggemann B, Jacobsen L, Dreborg S et al. Five-year follow-up on the PAT study: specific immunotherapy and long-term prevention of asthma in children. Allergy 2006;61:855-9
138. Eng PA, Reinhold M, Gnehm HP. Long-term efficacy of preseasonal grass pollen immunotherapy in children. Allergy 2002;57:306-12
139. Eng PA, Borer-Reinhold M, Heijnen IA, Gnehm HP. Twelve-year follow-up after discontinuation of preseasonal grass pollen immunotherapy in childhood. Allergy 2006;61:198-201
140. Purello-D'Ambrosio F, Gangemi S, Merendino RA et al. Prevention of new sensitizations in monosensitized subjects submitted to specific immunotherapy or not. A retrospective study. Clin Exp Allergy 2001;31:1295-302
141. Pajno GB, Barberio G, De Luca F, Morabito L, and Parmiani S. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy 2001;31:1392-7
142. Di Rienzo V, Marcucci F, Puccinelli P et al. Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study. Clin Exp Allergy 2003;33:206-10
143. Marogna M, Spadolini I, Massolo A, Canonica GW, Passalacqua G. Long-lasting effects of sublingual immunotherapy according to its duration: a 15-year prospective study. J Allergy Clin Immunol 2010;126:969-75
144. Novembre E, Galli E, Landi F et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 2004;114:851-7
145. Marogna M, Spadolini I, Massolo A, Canonica GW, Passalacqua G. Randomized controlled open study of sublingual immunotherapy for respiratory allergy in real-life: clinical efficacy and more. Allergy 2004;59:1205-10
146. Valovirta E, Berstad AK, De Blic J et al. Design and recruitment for the GAP trial, investigating the preventive effect on asthma development of an SQ-standardized grass allergy immunotherapy tablet in children with grass pollen-induced allergic rhinoconjunctivitis. Clin Ther 2011;33:1537-46
147. Schmid-Grendelmeier P. Rekombinante Allergene. Routinediagnostik oder Wissenschaft? Hautarzt 2010;61:946-53
148. Götzsche PC, Johansen HK. House dust mite control measures for asthma: systematic review. Allergy 2008;63:646-59
149. Kopp MV, Niggemann B, Forster J. House dust mite allergy: complete removal of the provoking allergen is a primary therapeutic approach. Allergy 2009;64:1402-3
150. Muche-Borowski C, Kopp M, Reese I et al. S3-Leitlinie Allergieprävention - Update 2009. Allergo J 2009;18:332-41
151. Pfaar O, Biedermann T, Klimek L, Sager A, Robinson DS. Depigmented-polymerized mixed grass/birch pollen extract immunotherapy is effective in polysensitized patients. Allergy 2013;68:1306-13
152. Nelson HS. Specific immunotherapy with allergen mixes: what is the evidence? Curr Opin Allergy Clin Immunol 2009;9:549-53
153. Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF), eds. Nationale Versorgungs Leitlinie Asthma - Langfassung, 2. Aufl. Version 5, 2009, zuletzt geä ndert: August 2013. www.leitlinien. de/nvl/asthma/mdb/downloads/nvl/asthma/asthma-2aufl-vers5-lang.pdf
154. Zuberbier T, Bachert C, Bousquet PJ et al. GA (2) LEN/EAA-CI pocket guide for allergen-specific immunotherapy for allergic rhinitis and asthma. Allergy 2010;65:1525-30
155. Demoly P, Piette V, Daures JP. Treatment of allergic rhinitis during pregnancy. Drugs 2003;63:1813-20
156. Wedi B, Rueff F. Pharmakoprophylaxe und Begleitmedikation bei spezifischer Immuntherapie. Hautarzt 2011;62:663-70
157. Fodeman J, Jariwala S, Hudes G, Jerschow E, Rosenstreich D. Subcutaneous allergen immunotherapy in 3 patients with HIV. Ann Allergy Asthma Immunol 2010;105:320-1
158. Randhawa IS, Junaid I, Klaustermeyer WB. Allergen immunotherapy in a patient with human immunodeficiency virus: effect on T-cell activation and viral replication. Ann Allergy Asthma Immunol 2007;98:495-7
159. Wöhrl S, Kinaciyan T, Jalili A, Stingl G, Moritz KB. Malignancy and specific allergen immunotherapy: the results of a case series. Int Arch Allergy Immunol 2011;156:313-9
160. Müller UR, Haeberli G. Use of beta-blockers during immunotherapy for Hymenoptera venom allergy. J Allergy Clin Immunol 2005;115:606-10
161. Linneberg A, Madsen F, Skaaby T. Allergen-specific immunotherapy and risk of autoimmune disease. Curr Opin Allergy Clin Immunol 2012;12:635-9
162. Linneberg A, Jacobsen RK, Jespersen L, Abildstrom SZ. Association of subcutaneous allergen-specific immunotherapy with incidence of autoimmune disease, ischemic heart disease, and mortality. J Allergy Clin Immunol 2012;129:413-9
163. Arzneimittelkommission der deutschen Ärzteschaft (AkdÄ), ed. Stellungnahme der AkdÄ zur allergenspezifischen Immuntherapie. Dtsch Ärztebl 2007;104:A3355-7
164. Zylka-Menhorn V. Hyposensibilisierung bald nur noch durch "erfahrene Ärzte". Dtsch Ärztebl 1995;92:A-1434
165. Alvarez-Cuesta E, Bousquet J, Canonica GW, Durham SR, Malling HJ, Valovirta E. Standards for practical allergenspecific immunotherapy. Allergy 2006;61 Suppl 82:1-20
166. Klimek L. Umsetzung der EU-Richtlinie 2010/32/EU fordert verletzungssichere Spritzen: im HNO-Bereich ist hiervon insbesondere auch die subkutane Immuntherapie (SCIT) betroffen. HNO-Mitteilungen 2013;63:189
167. Fischer PJ, Friedrichs F. Praktische Durchfü hrung der Hyposensibilisierung. Monatsschr Kinderheilkd 2013;161:608-15
168. Calabria CW. Accelerated immunotherapy schedules. Curr Allergy Asthma Rep 2013;13:389-98
169. Calabria CW, Cox L. Accelerated immunotherapy schedules and premedication. Immunol Allergy Clin North Am 2011;31:251-63, ix
170. Pfaar O, Wolf H, Klimek L, Schnitker J, Wüstenberg E. Immunologic effect and tolerability of intra-seasonal subcutaneous immunotherapy with an 8-day up-dosing schedule to 10, 000 standardized quality-units: a doubleblind, randomized, placebo-controlled trial. Clin Ther 2012;34:2072-81
171. Canonica GW, Bousquet J, Casale T et al. Sublingual immunotherapy: World Allergy Organization Position Paper 2009. Allergy 2009;64 Suppl 91:1-59
172. Haynes R. Einleitung. In: Haynes RB, Taylor DW, Sackett DL. Compliance Handbuch. München: Oldenbourg; 1986. p. 11-8
173. Sondermann N, Shah-Hosseini K, Henkel K, Schwalfenberg A, Mösges R. Erfolgsfaktoren der Adherence bei Hyposensibilisierung. Allergologie 2011;34:441-6
174. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487-97
175. Baiardini I, Braido F, Bonini M, Compalati E, Canonica GW. Why do doctors and patients not follow guidelines? Curr Opin Allergy Clin Immunol 2009;9:228-33
176. Bousquet J, Khaltaev N, Cruz AA et al. Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA (2) LEN and AllerGen). Allergy 2008;63 Suppl 86:8-160
177. Senna G, Ridolo E, Calderon M, Lombardi C, Canonica GW, Passalacqua G. Evidence of adherence to allergenspecific immunotherapy. Curr Opin Allergy Clin Immunol 2009;9:544-8
178. Claes C, Mittendorf T, Graf Von Der Schulenburg JM. Persistenz und Frequenz von Verordnungen im Bereich der subkutanen allergenspezifischen Immuntherapie (SCIT) bei GKV-Patienten in Deutschland. Med Klin (Munich) 2009;104:536-42
179. Aschemann U, Schulte P, Hecker H. Untersuchung zur Compliance eines anwenderfreundlichen Allergoids. Allergo J 2010;19(S1):63
180. Egert-Schmidt A, Martin E, Müller U, Schulte M, Thum-Oltmer S. Patienten-Compliance in der Spezifischen Immuntherapie - Ein Vergleich von SCIT- und SLIT-Präparaten. Allergo J 2011;20(S1):S40
181. Senna G, Lombardi C, Canonica GW, Passalacqua G. How adherent to sublingual immunotherapy prescriptions are patients? The manufacturers' viewpoint. J Allergy Clin Immunol 2010;126:668-9
182. Sieber J, De Geest S, Shah-Hosseini K, Mösges R. Medication persistence with long-term, specific grass pollen immunotherapy measured by prescription renewal rates. Curr Med Res Opin 2011;27:855-61
183. Eberle P, Schreder H, Shah-Hosseini K, Mösges R. Medikamenten-Persistenz bei Kindern und Jugendlichen unter einer Langzeithyposensibilisierung mit Gräserpollenextrakten. Ergebnisse einer Versorgungsstudie anhand von Verordnungsdaten. Allergologie 2013;36:9-18
184. Przybilla B, Rueff F, Walker A et al. Diagnose und Therapie der Bienen- und Wespengiftallergie. Allergo J 2011;20:318-39
185. Cox L, Calderon M, Pfaar O. Subcutaneous allergen immunotherapy for allergic disease: examining efficacy, safety and cost-effectiveness of current and novel formulations. Immunotherapy 2012;4:601-16
186. Malling HJ. Minimising the risks of allergen-specific injection immunotherapy. Drug Saf 2000;23:323-32
187. Kelso JM. The rate of systemic reactions to immunotherapy injections is the same whether or not the dose is reduced after a local reaction. Ann Allergy Asthma Immunol 2004;92:225-7
188. Vogelbruch M, Nuss B, Körner M, Kapp A, Kiehl P, Bohm W. Aluminium-induced granulomas after inaccurate intradermal hyposensitization injections of aluminium-adsorbed depot preparations. Allergy 2000;55:883-7
189. Netterlid E, Hindsén M, Björk J et al. There is an association between contact allergy to aluminium and persistent subcutaneous nodules in children undergoing hyposensitization therapy. Contact Dermatitis 2009;60:41-9
190. Frost L, Johansen P, Pedersen S, Veien N, Ostergaard PA, Nielsen MH. Persistent subcutaneous nodules in children hyposensitized with aluminium-containing allergen extracts. Allergy 1985;40:368-72
191. Lopez S, Pelaez A, Navarro LA, Montesinos E, Morales C, Carda C. Aluminium allergy in patients hyposensitized with aluminium-precipitated antigen extracts. Contact Dermatitis 1994;31:37-40
192. Ragusa FV, Passalacqua G, Gambardella R et al. Nonfatal systemic reactions to subcutaneous immunotherapy: a 10-year experience. J Investig Allergol Clin Immunol 1997;7:151-4
193. Burks AW, Calderon MA, Casale T et al. Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report. J Allergy Clin Immunol 2013;131:1288-96.e3
194. Epstein TG, Liss GM, Murphy-Berendts K, Bernstein DI. AAAAI and ACAAI surveillance study of subcutaneous immunotherapy, year 3: what practices modify the risk of systemic reactions? Ann Allergy Asthma Immunol 2013;110:274-8, 278.e1
195. Bernstein DI, Wanner M, Borish L, Liss GM, Immunotherapy Committee AAoAA, and Immunology: Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001. J Allergy Clin Immunol 2004;113, 1129-36.
196. Lüderitz-Püchel U, Keller-Stanislawski B, Haustein D. Neubewertung des Risikos von Test- und Therapieallergenen. Eine Analyse der UAW-Meldungen von 1991 bis 2000. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz 2001;44:709-18
197. Makatsori M, Calderon MA. Anaphylaxis: still a ghost behind allergen immunotherapy. Curr Opin Allergy Clin Immunol 2014;14(4):316-22
198. Cox L, Larenas-Linnemann D, Lockey RF, Passalacqua G. Speaking the same language: The World Allergy Organization subcutaneous immunotherapy systemic reaction grading system. J Allergy Clin Immunol 2010;125:569-74, 574.e1-574.e7
199. Nielsen L, Johnsen CR, Mosbech H, Poulsen LK, Malling HJ. Antihistamine premedication in specific cluster immunotherapy: a double-blind, placebo-controlled study. J Allergy Clin Immunol 1996;97:1207-13
200. Reimers A, Hari Y, Müller U. Reduction of side-effects from ultrarush immunotherapy with honeybee venom by pretreatment with fexofenadine: a double-blind, placebo-controlled trial. Allergy 2000;55:484-8
201. Cox LS, Larenas Linnemann D, Nolte H, Weldon D, Finegold I, Nelson HS. Sublingual immunotherapy: a comprehensive review. J Allergy Clin Immunol 2006;117:1021-35
202. Calderon MA, Simons FE, Malling HJ, Lockey RF, Moingeon P, Demoly P. Sublingual allergen immunotherapy: mode of action and its relationship with the safety profile. Allergy 2012;67:302-11
203. Passalacqua G, Garelli V, Sclifo F, Canonica GW. Sublingual immunotherapy for allergic rhinitis and conjunctivitis. Immunotherapy 2013;5:257-64
204. De Groot H, Bijl A. Anaphylactic reaction after thefirst dose of sublingual immunotherapy with grass pollen tablet. Allergy 2009;64:963-4
205. Passalacqua G, Baena-Cagnani CE, Bousquet J et al. Grading local side effects of sublingual immunotherapy for respiratory allergy: speaking the same language. J Allergy Clin Immunol 2013;132:93-8
206. Swissmedic, ed. Neues Heilmittelgesetz: Meldepflicht der Fachleute für unerwünschte Arzneitmittelwirkungen. Schweiz Ärztezeitung 2002;83:819-22
207. Ring J, Beyer K, Biedermann T et al. Guideline for acute therapy and management of anaphylaxis. S2 Guideline of the German Society for Allergology and Clinical Immunology (DGAKI), the Association of German Allergologists (AeDA), the Society of Pediatric Allergy and Environmental Medicine (GPA), the German Academy of Allergology and Environmental Medicine (DAAU), the German Professional Association of Pediatricians (BVKJ), the Austrian Society for Allergology and Immunology (ÖGAI), the Swiss Society for Allergy and Immunology (SGAI), the German Society of Anaesthesiology and Intensive Care Medicine (DGAI), the German Society of Pharmacology (DGP), the German Society for Psychosomatic Medicine (DGPM), the German Working Group of Anaphylaxis Training and Education (AGATE) and the patient organization German Allergy and Asthma Association (DAAB) Allergo J Int 2014;23:96-112
208. Simons FE, Ardusso LR, Bilo MB et al. 2012 Update: World Allergy Organization Guidelines for the assessment and management of anaphylaxis. Curr Opin Allergy Clin Immunol 2012;12:389-99
209. Dhami S, Panesar SS, Rader T et al. The acute and longterm management of anaphylaxis: protocol for a systematic review. Clin Transl Allergy 2013;3:14
210. Reeve L, Baldrick P, Hewings S, Skinner M. A battery of genotoxicity studies with an allergy vaccine adjuvanted with monophosphoryl lipid A (MPL (R)) for the treatment of grass pollen allergy. J Appl Toxicol 2012;32:608-16
211. Pfaar O, Cazan D, Klimek L, Larenas-Linnemann D, Calderon MA. Adjuvants for immunotherapy. Curr Opin Allergy Clin Immunol 2012;12:648-57
212. Jutel M, Solarewicz-Madejek K, Smolinska S. Recombinant allergens: The present and the future. Hum Vaccin Immunother 2012;8:1534-43
213. Patel D, Couroux P, Hickey P et al. Fel d 1-derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: a randomized, placebo-controlled study. J Allergy Clin Immunol 2013;131:103-9.e1-7
214. Johansen P, Von Moos S, Mohanan D, Kündig TM, Senti G. New routes for allergen immunotherapy. Hum Vaccin Immunother 2012;8:1525-33
215. Senti G, Prinz Vavricka BM, Erdmann I et al. Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial. Proc Natl Acad Sci U S A 2008;105:17908-12
216. Senti G, Von Moos S, Tay F et al. Epicutaneous allergenspecific immunotherapy ameliorates grass pollen-induced rhinoconjunctivitis: A double-blind, placebo-controlled dose escalation study. J Allergy Clin Immunol 2012;129:128-35
217. Senti G, Crameri R, Kuster D et al. Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections. J Allergy Clin Immunol 2012;129:1290-6
218. Kopp MV. Role of immunmodulators in allergen-specific immunotherapy. Allergy 2011;66:792-7
219. Larenas-Linnemann D, Wahn U, Kopp M. Use of omalizumab to improve desensitization safety in allergen immunotherapy. J Allergy Clin Immunol 2014;133:937.e2
220. Noon L. Prophylactic inoculation against hay fever. Lancet 1911;1:1572-3
221. Bousquet J, Schünemann HJ, Samolinski B et al. Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs. J Allergy Clin Immunol 2012;130:1049-62